Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruijuan Xu

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Plos One|December 3, 2014
A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly populationRuijuan Xu, Xiaoquan Liu, Jin Yang
European Journal of Clinical Pharmacology|February 18, 2018
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxabanRuijuan Xu, Weihong Ge, Qing Jiang
Cellular Signalling|December 3, 2020
Alkaline ceramidase family: The first two decadesRuijuan Xu, Paul Antwi Boasiako, Cungui Mao
British Journal of Clinical Pharmacology|July 15, 2017
Quantitative efficacy of topical administration of tranexamic acid on postoperative bleeding in total knee arthroplastyRuijuan Xu, Dongquan Shi, Weihong Ge, et al.
Frontiers in Medicine|April 15, 2026
Effectiveness of taking sequential mechanical ventilation in AECOPD with respiratory failure and risk factors for treatment failureRuijuan Xu, Haichao Liu, Yurong Liu, et al.
Biopharmaceutics & Drug Disposition|August 22, 2015
Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazoneQingqing Xiao, Liling Tang, Ruijuan Xu, et al.
British Journal of Clinical Pharmacology|February 2, 2021
Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populationsRuijuan Xu, Hong Tang, Lin Chen, et al.
Advances in Experimental Medicine and Biology|May 3, 2022
Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver CancerKai Wang, Yiran Wei, Ruijuan Xu, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 27, 2023
Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contributionRuijuan Xu, Wenyuan Liu, Weihong Ge, et al.
European Journal of Clinical Pharmacology|June 20, 2024
Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancerMeiyu Pan, Yan Lin, Yinhui Liu, et al.
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Plos One|December 3, 2014
A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly populationRuijuan Xu, Xiaoquan Liu, Jin Yang
European Journal of Clinical Pharmacology|February 18, 2018
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxabanRuijuan Xu, Weihong Ge, Qing Jiang
Cellular Signalling|December 3, 2020
Alkaline ceramidase family: The first two decadesRuijuan Xu, Paul Antwi Boasiako, Cungui Mao
British Journal of Clinical Pharmacology|July 15, 2017
Quantitative efficacy of topical administration of tranexamic acid on postoperative bleeding in total knee arthroplastyRuijuan Xu, Dongquan Shi, Weihong Ge, et al.
Frontiers in Medicine|April 15, 2026
Effectiveness of taking sequential mechanical ventilation in AECOPD with respiratory failure and risk factors for treatment failureRuijuan Xu, Haichao Liu, Yurong Liu, et al.
Biopharmaceutics & Drug Disposition|August 22, 2015
Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazoneQingqing Xiao, Liling Tang, Ruijuan Xu, et al.
British Journal of Clinical Pharmacology|February 2, 2021
Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populationsRuijuan Xu, Hong Tang, Lin Chen, et al.
Advances in Experimental Medicine and Biology|May 3, 2022
Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver CancerKai Wang, Yiran Wei, Ruijuan Xu, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 27, 2023
Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contributionRuijuan Xu, Wenyuan Liu, Weihong Ge, et al.
European Journal of Clinical Pharmacology|June 20, 2024
Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancerMeiyu Pan, Yan Lin, Yinhui Liu, et al.
Pageof 10